이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

2026년 8월 26일 업데이트: Hua Huang, MD, PhD

A Prospective, Multicenter, Phase III Randomized Controlled Trial Evaluating the Impact of Radical Surgery Versus Non-Surgery on Prognosis and Quality of Life in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy (ALANO Study, CGCA2603 Study)

The goal of this clinical trial is to learn if radical surgery improves prognosis and quality of life compared with continued standard non-surgical treatment in gastric cancer patients with peritoneal metastasis who have achieved successful conversion therapy. The main questions it aims to answer are:

  • Does radical surgery prolong overall survival in patients who achieve successful conversion therapy?
  • Does radical surgery provide better or at least comparable quality of life and safety outcomes compared with continued standard treatment? Researchers will compare radical surgery versus continued standard systemic treatment to see whether radical surgery provides superior clinical benefit for patients after successful conversion therapy.

Participants will:

  • Initial laparoscopic exploration confirms CY0P1 or CY1P1, absence of distant organ metastasis, a PCI ≤ 20, and presence or absence of ascites.
  • Receive conversion therapy (chemotherapy, targeted/immunotherapy, intraperitoneal therapy, etc.) per standard guidelines, tailored to the patient's condition and molecular-pathological profile
  • If clinical conversion is confirmed, undergo a second laparoscopic exploration to verify successful conversion
  • If successful conversion is confirmed (peritoneal lesions cleared or markedly regressed with negative biopsy, no ascites or distant metastases, R0-resectable primary tumor, and improved patient condition), be randomized 1:1 to either the surgery group or the standard treatment group
  • In the surgery group, undergo curative gastrectomy with D2 lymphadenectomy during the second laparoscopy, followed by adjuvant therapy and maintenance treatment
  • In the standard treatment group, continue systemic therapy without surgery, with maintenance treatment and salvage surgery permitted if clinically indicated
  • Complete quality of life questionnaires at predefined time points
  • Be followed up for survival, disease progression, adverse events and medical resource use outcomes

연구 개요

연구 유형

중재적

등록 (추정된)

170

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100853
        • Chinese PLA General Hospital
        • 연락하다:
      • Beijing, Beijing Municipality, 중국, 102206
        • Peking University International Hospital
        • 연락하다:
      • Beijing, Beijing Municipality, 중국, 100142
        • Peking University Cancer Hospital
        • 연락하다:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, 중국, 400038
        • The First Affiliated Hospital of Army Medical University
        • 연락하다:
    • Fujian
      • Zhangzhou, Fujian, 중국, 363000
        • Zhangzhou Affiliated hospital of Fujian Medical University
    • Guangdong
      • Guangzhou, Guangdong, 중국, 510060
        • Sun Yat-sen University Cancer Center
        • 연락하다:
      • Guangzhou, Guangdong, 중국, 510515
        • Nanfang Hospital, Southern Medical University
        • 연락하다:
      • Guangzhou, Guangdong, 중국, 510655
        • The Sixth Affiliated Hospital, Sun Yat-sen University
        • 연락하다:
    • Hubei
      • Wuhan, Hubei, 중국, 430030
        • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
        • 연락하다:
    • Jiangsu
      • Nanjing, Jiangsu, 중국, 210029
        • Jiangsu Province Hospital
        • 연락하다:
      • Nanjing, Jiangsu, 중국, 210009
        • Jiangsu Cancer Hospital
        • 연락하다:
      • Nanjing, Jiangsu, 중국, 210008
        • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine School
        • 연락하다:
      • Nantong, Jiangsu, 중국, 226001
        • Nantong First People's Hospital
        • 연락하다:
    • Jiangxi
      • Nanchang, Jiangxi, 중국, 330006
        • The First Affiliated Hospital of Nanchang University
        • 연락하다:
      • Nanchang, Jiangxi, 중국, 330006
        • The Second Affiliated Hospital of Nanchang University
        • 연락하다:
      • Shangrao, Jiangxi, 중국, 334000
        • Shangrao People's Hospital
        • 연락하다:
    • Jilin
      • Changchun, Jilin, 중국, 130021
        • The First Hospital of Jilin University
        • 연락하다:
    • Liaoning
      • Dalian, Liaoning, 중국, 116011
        • The First Affiliated Hospital of Dalian Medical University
        • 연락하다:
    • Shaanxi
      • Xi'an, Shaanxi, 중국, 710061
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • 연락하다:
      • Xi'an, Shaanxi, 중국, 710038
        • The Second Affiliated Hospital of Airforce Military Medical University
        • 연락하다:
    • Shandong
      • Jinan, Shandong, 중국, 250021
      • Jinan, Shandong, 중국, 250014
        • The First Affiliated Hospital of Shandong First Medical University
        • 연락하다:
      • Qingdao, Shandong, 중국
        • The Affiliated Hospital of Qingdao University
        • 연락하다:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, 중국, 200032
        • Fudan University Shanghai Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Hua Huang, MD,PHD
      • Shanghai, Shanghai Municipality, 중국
        • Shanghai General Hospital
        • 연락하다:
    • Shanxi
      • Changzhi, Shanxi, 중국, 046000
        • Changzhi People'S Hospital
        • 연락하다:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, 중국, 300060
        • Tianjin Medical University Cancer Institute&Hospital
        • 연락하다:
    • Xinjiang
      • Ürümqi, Xinjiang, 중국, 830011
        • Affiliated Cancer Hospital of Xinjiang Medical University
        • 연락하다:
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310022
        • Zhejiang Cancer Hospital
        • 연락하다:
      • Hangzhou, Zhejiang, 중국, 310009
        • The Second Affiliated Hospital Zhejiang University School of Medicine
        • 연락하다:
      • Hangzhou, Zhejiang, 중국, 310016
        • Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  • Patients voluntarily participate in the study, sign the informed consent form, and demonstrate good compliance.
  • Age ≥ 18 years and ≤ 70 years.
  • Histologically and/or cytologically confirmed gastric cancer.
  • No evidence of gastric outlet obstruction or intestinal obstruction.
  • No distant metastasis on imaging examination. Initial laparoscopic exploration confirms CY0P1 or CY1P1, without distant organ metastasis, with a recorded peritoneal carcinomatosis index (PCI) ≤ 20, and with either positive or negative ascites. Patients meeting these criteria are eligible for pre-enrollment. Following successful conversion therapy, a second laparoscopic exploration must confirm conversion to CY0P0, with no distant organ metastases and no regional lymph node metastases beyond the second station. Only upon meeting these criteria are patients formally enrolled in the study.
  • No prior chemotherapy, targeted therapy, or immunotherapy.
  • ECOG performance status score of 0-2.
  • Life expectancy ≥ 12 weeks.
  • Laboratory requirements: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L, platelet count ≥ 75 × 10⁹/L, hemoglobin ≥ 8 g/dL; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); total bilirubin ≤ 1.5 × ULN. In the presence of liver metastases, AST and ALT ≤ 5 × ULN; Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (CCr) ≥ 60 mL/min; International normalized ratio (INR) ≤ 1.5 × ULN; prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.

Exclusion Criteria:

  • Initial laparoscopic exploration reveals P0, or either of the two laparoscopic explorations reveals distant organ metastasis or distant lymph node metastasis.
  • Prior anticancer therapy, including chemotherapy, targeted therapy, or immunotherapy.
  • Hypertension that cannot be adequately controlled with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg).
  • Active bleeding or coagulation disorder within 2 months prior to enrollment, bleeding tendency, or ongoing thrombolytic therapy, deemed by the investigator as unsuitable for enrollment.
  • Active cardiac disease within 6 months prior to treatment, including myocardial infarction, severe/unstable angina pectoris. Left ventricular ejection fraction (LVEF) < 50% on echocardiography, or poorly controlled arrhythmia.
  • Known allergy to immunotherapy agents, chemotherapy agents, or any of their excipients.
  • Pregnancy (positive pregnancy test prior to treatment initiation) or breastfeeding.
  • Active or uncontrolled severe infection: Severe infection within 4 weeks prior to enrollment (e.g., requiring intravenous antibiotics, antifungals, or antivirals); Known human immunodeficiency virus (HIV) infection; History of clinically significant liver disease, including viral hepatitis. For known hepatitis B virus (HBV) carriers, active HBV infection must be excluded, defined as HBV DNA positive (> 1 × 10⁴ copies/mL or > 2000 IU/mL); Known hepatitis C virus (HCV) infection with positive HCV RNA (> 1 × 10³ copies/mL), or other hepatitis, cirrhosis.
  • Urinalysis indicating proteinuria ≥ 2+, with 24-hour urine protein quantification > 1.0 g.
  • Any other condition deemed by the investigator as inappropriate for participation in this study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Surgery Group
Patients undergo curative gastrectomy with D2 lymphadenectomy (laparoscopic, robotic, or open) during second-look laparoscopy after successful conversion therapy. Postoperatively, they receive adjuvant systemic therapy (continuing the preoperative regimen or MDT-modified protocol) for up to 8 cycles total, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal.
활성 비교기: Standard Treatment Group
Patients do not undergo surgery. They continue the original conversion regimen or an MDT-adjusted systemic therapy for a total of 8 cycles, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal. Salvage surgery is permitted if clinically indicated.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Overall Survival (OS)
기간: Up to 3 years after randomization
Up to 3 years after randomization

2차 결과 측정

결과 측정
측정값 설명
기간
Quality of Life (QoL) assessed by EORTC QLQ-C30 questionnaires
기간: Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Quality of Life (QoL) assessed by EORTC QLQ-STO22 questionnaires
기간: Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Pathological Complete Response (pCR) Rate
기간: At the time of radical surgery
At the time of radical surgery
R0 Resection Rate
기간: At the time of radical surgery
At the time of radical surgery
Complication-Free Survival
기간: Up to 3 years after randomization
Up to 3 years after randomization
Major Complication Rate
기간: Within 30 days and 90 days after surgery
Within 30 days and 90 days after surgery
Progression-Free Survival (PFS) and Peritoneal PFS
기간: Up to 3 years after randomization
Up to 3 years after randomization
Time to Peritoneal Re-dissemination
기간: Up to 3 years after randomization
Up to 3 years after randomization
Length of Hospital Stay
기간: Perioperative period
Duration of postoperative hospital stay, calculated from the date of surgical intervention to the date of hospital discharge, only applicable to participants receiving surgical treatment.
Perioperative period
Readmission Rate
기간: Within 30 days and 90 days post-surgery
Within 30 days and 90 days post-surgery
Treatment Interruption Rate
기간: Within 1-year after randomization
Within 1-year after randomization
Direct Medical Costs / Hospitalization Costs
기간: Baseline through study completion, an average of 3-years post-randomization
Direct medical costs are defined as all medical expenses directly related to the patient's care, including hospitalization, surgery, medications, laboratory tests, imaging examinations, and management of complications. Data will be collected continuously throughout the study period (from baseline until death or study completion) and aggregated at the end of the study.
Baseline through study completion, an average of 3-years post-randomization

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 10월 1일

기본 완료 (추정된)

2031년 10월 1일

연구 완료 (추정된)

2031년 10월 1일

연구 등록 날짜

최초 제출

2026년 8월 23일

QC 기준을 충족하는 최초 제출

2026년 8월 26일

처음 게시됨 (실제)

2026년 8월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 27일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 26일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual-participant-level raw data will not be shared externally. Aggregated study results will be published in peer-reviewed journals.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다